Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients (2016) Hein A, Gaß P, Walter CB, Taran FA, Hartkopf A, Overkamp F, Kolberg HC, et al. Journal article Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial (2015) Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, et al. Journal article Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial (2014) Mueller V, Gade S, Steinbach B, Loibl S, Von Minckwitz G, Untch M, Schwedler K, et al. Journal article HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics (2014) Fasching PA, Weihbrecht S, Haeberle L, Gasparyan A, Villalobos IE, Ma Y, Ekici AB, et al. Journal article Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma (2014) Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, Fasching P, et al. Journal article Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies (2014) Salmen J, Neugebauer J, Fasching P, Häberle L, Huober J, Woeckel A, Rauh C, et al. Journal article Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis (2013) Loehberg CR, Almstedt K, Jud S, Haeberle L, Fasching P, Hack C, Lux MP, et al. Journal article Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial (2010) Witzel I, Loibl S, Von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, et al. Journal article Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial (2010) Löhberg C, Jud S, Häberle L, Heusinger K, Dilbat G, Hein A, Rauh C, et al. Journal article